Bristol Myers Squibb (BMY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Bristol Myers Squibb (BMY)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

55.86

+0.29 (0.51%)

as of Jun 9, 2026, 3:47:50 pm Market Open.

161 watching

Investor Insights

Jun 9, 2026, 12:00 am

This summary was created by AI, based on 9 opinions in the last 12 months.

Bristol Myers Squibb (BMY-N) has garnered mixed reviews from various experts. Many have noted its attractive dividend and promising drug pipeline, while emphasizing its reasonable valuation and wide economic moat. Recent performance metrics were strong, with earnings per share (EPS) and sales exceeding analyst estimates, leading management to revise revenue projections upwards for 2025. However, concerns have also surfaced regarding the declining sales from its legacy portfolio, with some experts expressing disappointment in the performance of its Cobenfy drug and urging caution. Overall, opinions vary significantly, indicating that investors should weigh both the growth potential and the challenges ahead when considering this stock.

Consensus

Mixed

Valuation

Undervalued

Similar

PFE

DON'T BUY

Has had a lot of problems. Starting to clear up, but will take awhile.

WEAK BUY

DON'T BUY

Has had problems in manufacturing, shipping and FDA approvals. Exoects slow earnings growth.

BUY

Likes the valuations. Good balance sheet and good earnings.

BUY

Looks cheap. There is an SEC investigation going on.

DON'T BUY

Now is a good time for drug stocks, but this company has corporate problems.

BUY

9.25% dividend. Has been hit hard. Stable cash flow.

TOP PICK

Has been oversold. Very cheap. Could be a takeover.

DON'T BUY

Could drop. Prefers generic drugs.

BUY

Good drug company, but had difficulties getting FDA approvals. Good dividend. Cheap.

BUY

Made some poor moves. Still a triple A company.

PAST TOP PICK

(Was a top pick on May 23. Down 31%). Fell with health care. Price looks very good.

BUY

Trading at 5 X Book. Good dividends. New drug has approval.

BUY

Likes the drug sector. Prefers Pfizer.

DON'T BUY

Doesn't expect much growth, plus there are some issues.

Showing 196 to 210 of 221 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Bristol Myers Squibb (BMY)